Item Type | Name |
Concept
|
Bone Marrow Cells
|
Concept
|
Bone Marrow Diseases
|
Concept
|
Bone Marrow
|
Concept
|
Bone Marrow Transplantation
|
Concept
|
Bone Marrow Purging
|
Academic Article
|
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
|
Academic Article
|
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
|
Academic Article
|
Autologous and allogeneic transplantation for aggressive NHL.
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
Academic Article
|
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
|
Academic Article
|
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
|
Academic Article
|
Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?
|
Academic Article
|
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
Academic Article
|
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
Academic Article
|
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
|
Academic Article
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
|
Academic Article
|
Chimerism does not predict for outcome after alemtuzumab based conditioning.
|
Academic Article
|
Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation.
|
Academic Article
|
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants.
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
T-cell-depleted reduced-intensity conditioning transplantation for lymphoma: do donor lymphocyte infusions really matter?
|
Academic Article
|
Severe intestinal graft-versus-host disease following autologous stem cell transplantation.
|
Academic Article
|
Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
|
Academic Article
|
Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.
|
Academic Article
|
Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization.
|
Academic Article
|
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
|
Academic Article
|
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
|
Academic Article
|
Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients.
|
Academic Article
|
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
|
Academic Article
|
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.
|
Academic Article
|
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.
|
Academic Article
|
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
|
Academic Article
|
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
|
Academic Article
|
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
|
Academic Article
|
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.
|
Academic Article
|
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
|
Academic Article
|
Stem cell transplantation in follicular lymphoma: progress at last?
|
Academic Article
|
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
|
Academic Article
|
Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
Academic Article
|
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
|
Academic Article
|
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
|
Academic Article
|
Toxicity of single daily dose gentamicin in stem cell transplantation.
|
Academic Article
|
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.
|
Academic Article
|
Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
|
Academic Article
|
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
|
Academic Article
|
A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.
|
Academic Article
|
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
|
Academic Article
|
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.
|
Academic Article
|
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
|
Academic Article
|
Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow.
|
Academic Article
|
Allogeneic transplantation for low-grade lymphoma: long-term follow-up.
|
Academic Article
|
Treatment of relapse after allogeneic bone marrow transplantation.
|
Academic Article
|
Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
|
Academic Article
|
Human CD34+ HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis.
|
Academic Article
|
Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.
|
Academic Article
|
Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies.
|
Academic Article
|
Autologous bone marrow transplantation for leukemia and lymphoma.
|
Academic Article
|
High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
|
Academic Article
|
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
|
Academic Article
|
Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation.
|
Academic Article
|
Characteristics of engraftment after repeated autologous bone marrow transplantation.
|
Academic Article
|
Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield.
|
Academic Article
|
Characterization of human hematopoietic stem cells.
|
Academic Article
|
Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
|
Academic Article
|
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
|
Academic Article
|
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.
|
Academic Article
|
Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
|
Academic Article
|
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
|
Academic Article
|
Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro.
|
Academic Article
|
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities.
|
Academic Article
|
Allogeneic blood stem cell transplantation in advanced hematologic cancers.
|
Academic Article
|
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
|
Academic Article
|
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.
|
Academic Article
|
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
|
Academic Article
|
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
|
Academic Article
|
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
|
Academic Article
|
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
|
Academic Article
|
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
|
Academic Article
|
Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
|
Academic Article
|
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma.
|
Academic Article
|
Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization.
|
Academic Article
|
Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.
|
Academic Article
|
Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation.
|
Academic Article
|
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
|
Academic Article
|
A strategy to reduce donor-specific HLA Abs before allogeneic transplantation.
|
Academic Article
|
The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.
|
Academic Article
|
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
|
Academic Article
|
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
|
Academic Article
|
Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
|
Academic Article
|
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
|
Academic Article
|
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
|
Academic Article
|
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
|
Academic Article
|
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
|
Academic Article
|
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Allogeneic bone marrow transplantation for low-grade lymphoma.
|
Academic Article
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
|
Academic Article
|
Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
|
Academic Article
|
Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions.
|
Academic Article
|
High-dose melphalan allows durable engraftment of allogeneic bone marrow.
|
Academic Article
|
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.
|
Academic Article
|
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
|
Academic Article
|
The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma.
|
Academic Article
|
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
|
Academic Article
|
Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
|
Academic Article
|
Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease.
|
Academic Article
|
Peripheral-blood versus bone marrow stem cells.
|
Academic Article
|
Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
|
Academic Article
|
Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.
|
Academic Article
|
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
|
Academic Article
|
Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
|
Academic Article
|
Invasive Aspergillus sinusitis during bone marrow transplantation.
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
Academic Article
|
Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum.
|
Academic Article
|
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
|
Academic Article
|
DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center.
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
Academic Article
|
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.
|
Academic Article
|
Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.
|
Academic Article
|
Second allogeneic transplantation: ever? never? or sometimes.
|
Academic Article
|
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy.
|
Academic Article
|
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
|
Academic Article
|
Against the odds: haplo-cord grafts protect from GvHD and relapse.
|
Academic Article
|
Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors.
|
Academic Article
|
Preleukemic state preceding adult acute lymphoblastic leukemia.
|
Academic Article
|
Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
Academic Article
|
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.
|
Academic Article
|
Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients.
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
Academic Article
|
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
|
Academic Article
|
Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies.
|
Academic Article
|
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies.
|
Academic Article
|
Cord blood transplants supported by unrelated donor CD34+ progenitor cells.
|
Academic Article
|
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy.
|
Grant
|
Minor Histocompatilibity Vaccination After Allo-Transpl*
|
Academic Article
|
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD).
|